Lumira Capital Wins CVCA's 2013 VC Deal of the Year
Life sciences-focused venture capital firm Lumira Capital received the 2013 "Deal of the Year" award in the venture capital category from Canada’s Venture Capital & Private Equity Association. The firm won for its return on investment in KAI Pharmaceuticals Inc. The San Francisco-based bio-pharmaceuticals company was acquired last year by Amgen Inc. for US$315 million. Lumira's IRR on the KAI investment was 21% and the multiple of capital on its original investment was 3.9 times (current) and 4.2 times (final based on escrow release).
24 May 2013•5 mins read
